| scholarly article | Q13442814 |
| P50 | author | David Agus | Q5230638 |
| Mitchell Gross | Q55743787 | ||
| P2093 | author name string | Martina Uttenreuther-Fischer | |
| Michael S Gordon | |||
| David S Mendelson | |||
| Peter Stopfer | |||
| Yihua Zhao | |||
| Mahmoud Ould-Kaci | |||
| P2860 | cites work | Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). | Q35168977 |
| CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 | ||
| The ErbB receptors and their ligands in cancer: an overview. | Q36108987 | ||
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Q37054957 | ||
| Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy | Q37113427 | ||
| Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors | Q42948964 | ||
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies | Q43658492 | ||
| Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial | Q44135091 | ||
| ErbB targeted drugs and angiogenesis | Q50334563 | ||
| A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab | Q24594725 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | Q24653999 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas | Q28256478 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Q34263959 | ||
| Role of tyrosine kinase inhibitors in cancer therapy | Q34432091 | ||
| ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial | Q34522758 | ||
| Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer | Q34778936 | ||
| Why the epidermal growth factor receptor? The rationale for cancer therapy | Q34803451 | ||
| Epidermal growth factor receptor dependence in human tumors: more than just expression? | Q34803484 | ||
| Developing inhibitors of the epidermal growth factor receptor for cancer treatment. | Q35157038 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 409-416 | |
| P577 | publication date | 2012-12-15 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors | |
| P478 | volume | 31 |
| Q39008385 | A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors |
| Q35873072 | A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study |
| Q33556988 | A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors |
| Q33425698 | A phase I study of volasertib combined with afatinib, in advanced solid tumors |
| Q38197278 | Afatinib for the treatment of advanced non-small-cell lung cancer. |
| Q38829891 | Afatinib in squamous cell carcinoma of the head and neck |
| Q38215591 | Afatinib in the treatment of breast cancer |
| Q34896542 | Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c |
| Q38263148 | Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer |
| Q38179266 | Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer |
| Q38575289 | Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. |
| Q38132049 | Afatinib: first global approval |
| Q37650711 | Clinical Pharmacokinetics and Pharmacodynamics of Afatinib |
| Q37676327 | Drug monographs: afatinib and obinutuzumab |
| Q91603678 | Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer |
| Q21132357 | Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations |
| Q39954639 | Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis |
| Q45662172 | Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours |
| Q36750974 | Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours |
| Q39297048 | Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck |
| Q33839177 | Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy |
| Q38352587 | The Potential of panHER Inhibition in Cancer |
Search more.